Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
NECA Logo
  • NET Nurse
  • Donate
  • What are NETs?
    • What are Neuroendocrine Cancers?
    • What are Pheos & Paras?
    • NET Symptoms
    • NET Types
    • Causes
    • Treatments
    • Grades
    • Diagnosis
    • Prognosis
    Consider the Grey Area
  • Patients & Carers
    • Patient & Carer Support
    • Patient Resources
    • Optimal Care Pathway
    • NET Nurse
    • Patient Stories
    • Share your Story
    • Australian NET Specialists
    • Clinical Trials
    • Living with NETS
    • Specialist Support Services
    Consider the Grey Area
  • Healthcare Professionals
    • Optimal Care Pathway
    • Professional Learning
    • Patient Referral
    • Clinical Trials
    • NET Symptoms
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order Booklets & Resources
    Consider the Grey Area
  • Get Involved
    • Advocate for Us
    • Share your Story
    • Donate
    • Fundraise
    • Events
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Volunteer
    Senate MailChimp
  • March4NETs
NET Nurse
Donate

Home » Research » Sydney Cardiologists Perform World First

Sydney Cardiologists Perform World First

  • March 22, 2015

Carcinoid heart disease occurs in up to 20% of patients with symptoms of carcinoid syndrome (diarrhoea, flushing, abdominal pain, bronchospasm (asthma).
Excess serotonin, a hormone released by the NET tumours into the bloodstream affects the heart by causing thick ‘plaques’ within the heart muscle and damage to  valves (tricuspid and pulmonary) on the right side of the which become ‘tightly narrowed’ or ‘leaky’. Patients with carcinoid heart disease present with symptoms such as breathlessness, fatigue, enlarged liver and swollen ankles and without treatment can develop right heart failure.
Somatostatin analogues (octreotide, lanreotide etc) can slow the progression of carcinoid heart disease, however, some patients may need cardiac surgery to replace the narrowed or leaking valves to improve their symptoms and quality of life.  Cardiac surgery for valve replacement necessitates that the patient have open heart surgery and be put on ‘cardiopulmonary’ bypass machine while the cardiac surgeon replaces the valve. Some patients are too unwell or unwilling to undergo such significant surgery.

           

In a world first, two prominent Sydney interventional Cardiologists – Dr David Tanous and Dr Philip Roberts have percutaneously implanted an artificial valve into a NET patient, treating her narrowed pulmonary valve. In this procedure, a catheter was inserted into the femoral vein (in the groin) and with the assistance of x-ray imaging, an artificial valve was placed across the narrowed valve. Sheryl, who had been suffering from carcinoid heart disease for some time, now ‘feels well enough to return to work”.

   

On the day I saw her she proclaimed that she felt wonderful and had more energy and was surprised that her recovery time was so quick. The Unicorn Foundation is excited about the use of this treatment and its future potential in NET patients with symptomatic and significant carcinoid heart disease. Dr John Leyden

Share this post

Recent posts

VHL Awareness Month 2025

May 6, 2025

NET Patient Chris, from Ballarat, Raises Awareness of Neuroendocrine Cancer

May 5, 2025

Help Us Grow: Connect NECA with Corporate Partners to Make a Lasting Impact

April 29, 2025

Neuroendocrine Cancer Awareness Daily Mail 5 April 2025

April 5, 2025
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousThank You Tour De Cure
NextNET Nurse Service – Patient SurveyNext

Related Posts

NECA at ENETS 2025: Advancing NET Care on the Global Stage

NeuroEndocrine Cancer Australia at ENETS 2025: Advancing NET Care on the Global Stage NeuroEndocrine Cancer Australia (NECA) proudly represented Australia at the 22nd Annual European

The Australian Cancer Plan

Shaping the future of cancer control together   We are pleased to send you this update on the Australian Cancer Plan, the first national 10-year

Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness

Read full report

Peter MacCallum Cancer Centre – Recruiting NET health professionals for International Delphi survey

Recruiting NET health professionals for International Delphi survey Development of a neuroendocrine tumour (NET) nutrition-risk screening tool to identify patients requiring nutrition intervention and education

View All

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Patients & Carers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

Healthcare Professionals

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2025 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin